Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 22.4% – Still a Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares were up 22.4% during trading on Friday . The company traded as high as $0.41 and last traded at $0.40. Approximately 60,477,578 shares were traded during mid-day trading, a decline of 24% from the average daily volume of 79,476,109 shares. The stock had previously closed at $0.33.

Analyst Ratings Changes

Separately, StockNews.com started coverage on shares of Tonix Pharmaceuticals in a research report on Friday, January 17th. They issued a “hold” rating for the company.

Tonix Pharmaceuticals Stock Performance

The stock has a fifty day simple moving average of $0.27 and a 200-day simple moving average of $0.29. The stock has a market cap of $74.57 million, a P/E ratio of -0.01 and a beta of 2.02. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $1.80. The company had revenue of $2.82 million during the quarter, compared to analysts’ expectations of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. On average, equities analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current year.

Hedge Funds Weigh In On Tonix Pharmaceuticals

An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. PFG Investments LLC bought a new stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned about 0.12% of Tonix Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.